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Abstract 1 
Background 2 
The genetic component of Cannabis Use Disorder (CUD) may overlap with influences acting 3 
more generally on early stages of cannabis use. This paper aims to determine the extent to 4 
which genetic influences on the development of cannabis abuse/dependence are correlated 5 
with those acting on opportunity to use cannabis and frequency of use. 6 
Methods 7 
Cross-sectional study of 3303 Australian twins, measuring age of onset of cannabis use 8 
opportunity, lifetime frequency of cannabis use and lifetime DSM-IV cannabis 9 
abuse/dependence. A trivariate Cholesky decomposition estimated additive genetic (A), 10 
shared environment (C) and unique environment (E) contributions to opportunity to use 11 
cannabis, frequency of cannabis use, cannabis abuse/dependence, and the extent of 12 
overlap between genetic and environmental factors associated with each phenotype. 13 
Results 14 
Variance components estimates were A=0.64 (95% CI 0.58 – 0.70) and E=0.36 (95% CI 15 
0.29 – 0.42) for age of opportunity to use cannabis, A=0.74 (95% CI 0.66 – 0.80) and 16 
E=0.26 (95% CI 0.20 – 0.34) for cannabis use frequency, and A=0.78 (95% CI 0.65 – 0.88) 17 
and E=0.22 (95% CI 0.12 – 0.35) for cannabis abuse/dependence. Opportunity shares 45% 18 
of genetic influences with frequency of use, and only 17% of additive genetic influences are 19 
unique to abuse/dependence from those acting on opportunity and frequency. 20 
Conclusions 21 
There are significant genetic contributions to lifetime cannabis abuse/dependence, but a 22 
large proportion of this overlaps with influences acting on opportunity and frequency of use. 23 
Individuals without drug use opportunity are uninformative, and studies of drug use disorders 24 
must incorporate individual exposure to accurately identify aetiology. 25 
Introduction 26 
 3 
As the legislative landscape regarding cannabis alters, potentially altering patterns of use 1 
(Hopfer 2014; Hasin et al. 2015; Shi et al. 2015), a greater understanding of environmental 2 
and genetic influences on progression to harmful or disordered cannabis use is needed. 3 
Cannabis Use Disorder (CUD) is included in the DSM-5 (American Psychiatric Association & 4 
DSM-5 Task Force 2013), an amalgamated update of DSM-IV  cannabis abuse and 5 
cannabis dependence (American Psychiatric Association 2000) characterised by loss of 6 
control over use, failure to fulfil social roles, recurrent use in hazardous situations, and use 7 
despite worsening of health problems. An estimated 10% - 16% of individuals who have ever 8 
used cannabis will develop dependence (Anthony 2006) and globally 13.1 million individuals 9 
meet criteria for cannabis dependence contributing 10.3% of the illicit drug use global burden 10 
of disease (Degenhardt et al. 2014).  11 
Individuals with drug dependence pass through several intermediate stages before 12 
developing a clinical condition, and many non-clinical individuals will reach earlier stages of 13 
drug use involvement without progressing to disorder. The earliest stage of involvement is 14 
having the opportunity to use (regardless of whether the individual uses the drug or not). 15 
Opportunity is required for use to occur, and forms an individual’s earliest necessary 16 
condition from which they are at risk of developing dependence (Wagner & Anthony 2002). 17 
Once initiation of use has occurred, individuals will vary in frequency of cannabis use, with 18 
increased frequency associated with increased likelihood for the development of cannabis 19 
dependence (Chen et al. 1997). Considering the sources of variation in progression through 20 
the stages of cannabis use, and the extent to which influences are consist across different 21 
stages, can provide insight into the aetiology of CUD (Hines et al. 2015a, 2016).  22 
Twin modelling has identified a strong genetic contribution to CUD, with a review of 6 23 
studies in the area concluding heritability estimates range from 45% – 78% (Agrawal & 24 
Lynskey 2006). Meta-analysis estimated heritability of problematic cannabis use (having one 25 
or more of the symptoms of cannabis abuse or dependence) at 51.4 (95% CI 37.9–64.9) in 26 
males and 58.5 (95% CI 44.2–72.9) in females (Verweij et al. 2010). However, the 27 
 4 
magnitude of these influences may differ across stages of drug use. Early stages may be 1 
genetically influenced through personality traits such as novelty seeking (Laucht et al. 2007), 2 
whereas at subsequent stages, such as drug dependence and development of withdrawal, 3 
genetic influences on drug metabolism, may be more influential (Dick et al. 2014).  4 
Common genetic influences may act on multiple stages. The majority of research into the 5 
correlation of influences between initiation of use and disordered use comes from the alcohol 6 
and tobacco literature, where a genetic correlation (0.15 – 0.88) has been consistently 7 
demonstrated between the earlier and later stages of drug use (Broms et al. 2006; Pagan et 8 
al. 2006; Morley et al. 2007). Similarly, studies of alcohol use disorder have identified a 9 
strong genetic correlation between age of alcohol initiation and alcohol use disorder (Sartor 10 
et al. 2009; Ystrom et al. 2014). Similar mechanisms may be acting on CUD. Only 34% of 11 
the variance in cannabis abuse/dependence is unique to this phenotype, with the rest 12 
shared with genetic influences on initiation (Agrawal et al. 2005), and cannabis availability 13 
explains almost all the shared environmental risks in cannabis initiation and abuse (Gillespie 14 
et al. 2009b). 15 
To date, research has not explored the extent to which genetic influences may correlate 16 
across more than 2 stages of drug use. Additionally, the heritability of the earliest stage of 17 
drug use - having opportunity to use a drug (Wagner & Anthony 2002) – has been somewhat 18 
overlooked. This is despite evidence of the importance of this phenotype for design of 19 
genetic research (Nelson et al. 2013): individuals who do not have opportunity to use a 20 
substance are unable to express their genetic vulnerability to later stages, including use and 21 
use disorders. Not only are such individuals structurally missing in analytic terms, but 22 
excluding individuals who have no drug use opportunity to use from genetic association 23 
studies can provide superior control for environmental background and related covariates.  24 
Opportunity may be regarded as a putative environmental factor, likely subject to broader 25 
environmental modifications, such as changes in national policy, but also to individual-26 
specific factors, including peer provision of drugs. Despite these underpinnings, such 27 
 5 
“environmental” factors have been shown to have heritable variation (Kendler & Baker 2007; 1 
Gillespie et al. 2009b). Considering this phenotype in the context of later stages of drug 2 
transitions, such as escalation to frequent use and the development of abuse/dependence 3 
will provide insight into the pathways to the development of dependence.  4 
By applying trivariate twin models to the phenotypes age of cannabis opportunity, 5 
frequency of cannabis use, and abuse/dependence, this paper aims to determine the extent 6 
to which genetic influences on the development of cannabis abuse/dependence are unique 7 
to the phenotype, and the extent to which they correlate with influences on opportunity to 8 
use cannabis and the frequency of cannabis use. 9 
Methods  10 
Sample 11 
The sample was drawn from the Australian Twin Registry. From a pool of pairs born 1972-12 
1979, 3348 MZ and DZ twins completed the interview component of a study of cannabis and 13 
other drug misuse. A full description of the study methodology and of the characteristics of 14 
participants has been published previously (Lynskey et al. 2012). The 3303 twins who 15 
provided information on whether or not they had ever had the opportunity to use cannabis, 16 
and who had complete zygosity information, form the analysis sample for this paper. This 17 
sample consisted of 975 MZ males, 481 DZ males, 734 MZ females, 371 DZ females, and 18 
742 opposite sex DZ twins. Of these, 808 were singletons. Mean age was 31.8 (range 27 – 19 
40 years, median 32.0). 20 
Assessment 21 
Participants were assessed through computer-assisted telephone interviews which collected 22 
information on socio-demographics, childhood experiences, drug use and common mental 23 
health disorders, including cannabis and other drug use disorders, assessed using the Semi-24 
Structured Assessment for the Genetics of Alcoholism (SSAGA-OZ) interview (Bucholz et al. 25 
 6 
1994; Heath et al. 1997). The SSAGA-OZ is a validated measure of mental health using 1 
DSM-IV criteria, and includes assessment of cannabis and other drug abuse and 2 
dependence. Specific measures used in the current analyses are described below. 3 
Measures 4 
Opportunity to use cannabis 5 
Participants were asked “have you ever been offered, or had the opportunity to use 6 
cannabis, even if you didn't use it at the time? How old were you the first time?” Of 3348 7 
twins interviewed, 3325 provided information on whether or not they had ever had the 8 
opportunity to use cannabis. Of these twins, information on zygosity was missing for 22, 9 
resulting in an analysis sample of 3303. 10 
For analysis, participants were categorised as having never had the opportunity to use 11 
cannabis (N = 356, 10.8%), having had later opportunity to use cannabis (first opportunity 12 
reported as happening at age 16 and over, N = 2264, 68.5%), or having had early 13 
opportunity to use cannabis (first opportunity reported as occurring at age 15 or earlier, N = 14 
670, 20.3%). As there is no precedent in the literature for what age represents an “early” 15 
opportunity to use cannabis, sensitivity analyses were conducted on the cut-off age. The 16 
correlations obtained by different cut-off points indicated results were not affected by the 17 
choice of age 15 as age cut-off for early opportunity (see supplementary material). 18 
 19 
Cannabis use frequency 20 
Participants were asked about lifetime frequency of use through the item “have you used 21 
marijuana 40 or more times, 21-39 times, 11-20 times, 7-10 times, 1-6 times?”, then 22 
estimated number of times used. Participants were categorised as having used cannabis 23 
infrequently, at a level that precluded being asked about cannabis abuse/dependence (0 - 24 
11 times, N = 1913), moderately (12 – 50 times, N = 476), or high frequency (50+ times, 25 
N=554).  26 
 7 
Cannabis abuse/dependence 1 
Participants were classified as meeting DSM-IV criteria for lifetime cannabis abuse if they 2 
reported one or more of the following: often using cannabis in a situation where they might 3 
get hurt; arrested more than twice within a 12 month period as a result of their cannabis use; 4 
cannabis use having caused difficulty with work, study or household responsibilities; 5 
cannabis having caused social and interpersonal problems more than 3 times within a 12 6 
month period.  7 
Participants were classified as meeting lifetime criteria for DSM-IV cannabis dependence if 8 
they reported 3 or more of the following symptoms occurring within the same 12 month 9 
period: using cannabis a greater number of times/greater amount than was intended, 10 
tolerance, wanting to cut down/stop use, spending so much time obtaining/using/recovering 11 
from the effects of cannabis the participant had little time for anything else, reducing 12 
important activities as a result of cannabis use, continuing use despite it worsening 13 
health/emotional problems. In the sample used in this analysis, 16.4% (N=543) reported 14 
cannabis abuse and/or dependence. 15 
Individual characteristics 16 
Sex 17 
Sex was determined through self-report (76.9% female, N=2540).   18 
Zygosity 19 
Zygosity of twin pairs was measured through standard questions about physical similarity 20 
and the extent to which twin identity was confused by parents, teachers and strangers; 21 
methods found to give better than 95% agreement with results of genotyping (Cederlof et al. 22 
1961; Kasriel & Eaves 1976; Sarna et al. 1978). 23 
Statistical analyses 24 
All analyses were conducted using OpenMX v2.5.2 (Boker et al. 2011) for the statistical 25 
software R v3.1.2 (R Core Team 2013). Analyses used full information maximum-likelihood 26 
 8 
estimation with raw data, and the optimiser SLSQP was applied to analyses. Analyses were 1 
adjusted for sex. 2 
Staged Trivariate Twin Model 3 
Classical twin modelling estimates the extent to which additive genetic (A), common 4 
environment (C) and unique environment (E) influence a phenotype (Neale & Cardon 1992). 5 
Approaches using twins reared together can be used to determine the heritability of, and 6 
environmental contribution to, a phenotype or trait. Identical – or monozygotic (MZ) – twin 7 
pairs share 100% of their genetic material. Fraternal – or dizygotic (DZ) – twin pairs share 8 
only 50%, on average, of the same genetic material. This means they are no more 9 
genetically alike than full siblings. However, unlike siblings DZ twins will grow up in the same 10 
environment. Using this knowledge we can calculate the extent to which the variance in a 11 
phenotype is due to genetic effects, and the extent to which it is due to environmental effects 12 
(Plomin et al. 2013). If the MZ correlation is twice the DZ correlation then all twin-pair 13 
similarity can be attributed to A, whereas if the MZ correlation is greater than the DZ 14 
correlation, but not twice the DZ correlation, there is also evidence of some shared 15 
environmental influences. The extent to which the MZ twin correlation is less than 1.0 16 
indicates the magnitude of non-shared environmental influences. Dominant genetic effects 17 
(D), which are non-additive interaction effects between genes, cannot be assessed 18 
simultaneously with C (Neale & Cardon 1992). Structural equation modelling of twin data is 19 
used to obtain precise estimates of A, C and E and allows for the comparison of models and 20 
generation of confidence intervals around estimates (Neale & Cardon 1992). 21 
A staged twin model was fitted to assess contributions of A, C, and E to variance in age 22 
of opportunity to use cannabis, frequency of cannabis use, and lifetime cannabis 23 
abuse/dependence, and to estimate the extent to which the influences of A, C and E on the 24 
three phenotypes were correlated (Heath et al. 2002). The staged model is appropriate for 25 
situations where early-stage phenotypes, such as cannabis use opportunity, are necessary 26 
for the expression of later behaviours, such as the development of dependence, and is a 27 
 9 
variation of the classic bivariate model appropriate for analysis of variables with data missing 1 
at random (data are missing as a result of observations on a previous variable, as opposed 2 
to data missing completely at random) (Kendler et al. 1999; Heath et al. 2002; Neale et al. 3 
2006). See Heath et al (2002) for full details. Explicitly modelling such structurally missing 4 
data also has the advantage of estimating the extent of covariation between these 5 
contingent stages of use (i.e., opportunity, frequency, abuse/dependence) while not 6 
excluding those who do not provide information on a prior stage (e.g., opportunity) from 7 
analyses of later stages (e.g., abuse/dependence). 8 
A Cholesky decomposition model was used to parse the phenotypic correlations 9 
between the three stages of cannabis use and misuse into A, C and E sources, including 10 
those specific to each of the latter stages of frequency and abuse/dependence as well as the 11 
magnitude of overlapping influences across the 3 stages.  12 
Assumption testing 13 
The analysis assumes each threshold-selected trait has an underlying bivariate/multivariate 14 
normal liability distribution. Exploring this methodological issue falls beyond the scope of this 15 
paper, but such modelling techniques have been shown to be robust to breaches of this 16 
assumption (Reinartz et al. 2009). Thresholds represent cut-off points along this unobserved 17 
continuous distribution of liability. 18 
In order to test whether thresholds could be equated between MZ and DZ twins, nested 19 
models were compared against a saturated twin model. Differences in the fit of more 20 
parsimonious models compared to the saturated or ACE model were assessed via the 21 
Akaike Information Criterion (AIC) and the change in -2loglikelihood (Δ-2LL), which can be 22 
approximated by a chi square distribution with degrees of freedom (DF) equal to the 23 
difference in degrees of freedom of the nested models. Where these measures lead to 24 
different conclusions on parsimony, the p value has been prioritised. Significance of 25 
thresholds (and equality between thresholds) was determined by Δ-2LL and change in DF 26 
 10 
(ΔDF) and associated chi-square distribution. Significance of variance and covariance paths 1 
was similarly determined through likelihood ratio testing.  2 
 3 
Results 4 
Prevalence of, and Correlations between, Opportunity to use Cannabis, Frequency of 5 
Cannabis Use and Abuse/dependence 6 
Of those who reported opportunity to use cannabis by age 15 (N=683), 35.8% (N=244) 7 
reported high frequency cannabis use (lifetime use 50+ times), compared to 13.7% (N= 310) 8 
of those who reported cannabis use opportunity at age 16 or older (N=2264). Of those who 9 
reported high frequency cannabis use (50+ times, N=554), 75.6% (N =418) met criteria for 10 
lifetime cannabis abuse/dependence compared to 26.3% (N =125) of those who reported 11 
lower frequency cannabis use (12 – 50 times, N = 476). 12 
A saturated twin model was used to estimate tetrachoric correlations for the 13 
categorically-defined traits of age of opportunity, frequency of cannabis use and lifetime 14 
cannabis abuse/dependence (see Table 1). The relative magnitude of MZ within-trait 15 
correlations indicate heritable influences on all of these traits. The across twin/across trait 16 
correlations and confidence intervals indicate genetic factors contribute to all correlations. 17 
MZ within trait and across trait correlations are not twice the DZ correlations, suggesting 18 
some influence of C. All correlations are less than 1.0, suggesting moderate to low effects of 19 
E. 20 
Assumption Testing 21 
MZ and DZ thresholds could not be equated (Δ-2LL=15.0, ΔDF=5, P=0.01), and were 22 
estimated separately in all further models. 23 
Trivariate Cholesky Model Fitting 24 
 11 
A saturated model provided fit statistics, estimates for each component of the variance for all 1 
three phenotypes, and estimates for the covariance between phenotypes. The fit statistics 2 
for this model were -2LL=11029.68 DF=7249, AIC=--3468.32. 3 
Nesting Models to Develop Parsimonious Model Fit 4 
In order to identify the most parsimonious model, nested models constrained individual 5 
variance and covariance components to zero, when confidence intervals on the estimate 6 
from the saturated model included 0. It was possible to drop all C parameters (Δ-2LL=6.07, 7 
ΔDF=6, P value=0.41) without a significant decrement in fit. In addition, there was no 8 
statistically significant covariance between opportunity and either frequency or 9 
abuse/dependence attributable to E (Δ-2LL=0.58, ΔDF=2, P value=0.75). 10 
Final Model 11 
The final most parsimonious model was an AE model (Δ-2LL=7.22, ΔDF=8, P value=0.51). 12 
Variance component estimates are presented in Table 2. Approximately 64-78% of the 13 
variance in each phenotype was due to additive genetic influences, with confidence intervals 14 
indicating both frequency and abuse/dependence were modestly, but significantly, more 15 
heritable than opportunity to use. A proportion of these genetic influences were shared 16 
across the three stages. As shown in Table 2, genetic correlations across stages ranged 17 
from 0.37 (opportunity and abuse/dependence) to 0.68 (frequency and abuse/dependence). 18 
For frequency, about 55% of the genetic influences were unique from those acting on 19 
opportunity, while for cannabis abuse/dependence, 17% of the genetic influences were 20 
unique from those acting on opportunity and frequency of use. In addition, cannabis 21 
abuse/dependence shared individual-specific environmental influences with frequency (but 22 
not opportunity) with 27% specific to this stage. 23 
Discussion 24 
 12 
Additive genetic influences determine the majority of variance in age of opportunity to use 1 
cannabis (0.64, 95% CI 0.58 – 0.70), frequency of cannabis use (0.74, 95% 0.66 – 0.80), 2 
and cannabis abuse/dependence (0.78, 95% 0.65 – 0.88). Of these influences, 55% of 3 
additive genetic influences acting on frequency of cannabis use are unique from those acting 4 
on age of opportunity to use cannabis, and 17% of additive genetic influences acting on 5 
cannabis abuse/dependence are unique from those acting on opportunity and frequency. No 6 
significant effect of the shared environment was observed, but there were unique 7 
environmental influences on all phenotypes. The only correlated unique environmental 8 
influences were between cannabis use frequency and abuse/dependence. 9 
 10 
Previous research has not explored the correlation between influences on cannabis use 11 
opportunity and cannabis abuse or dependence, although existing studies focusing on 12 
cannabis initiation observed overlapping liabilities between cannabis initiation and 13 
progression to heavy use (0.88; 33% due to genetic factors) (Fowler et al. 2007). This is a 14 
similar genetic contribution to the overlap in liabilities to that presently observed between 15 
cannabis opportunity and frequency of use. This demonstrates the present findings are in 16 
line with existing research showing genetic correlation between the early stages of cannabis 17 
use and later substance use disorders.  18 
Opportunity to use cannabis is the necessary first step in progression towards 19 
problematic use, and this phenotype could be expected to be subject only to environmental 20 
influence. However, 64% of the variance in cannabis age at opportunity was due to genetic 21 
factors. Although it may be surprising that an apparently environmental phenotype is 22 
influenced by heritable factors, this result is consistent with previous findings that cannabis 23 
use availability (Gillespie et al. 2009b) and other putative measures of ‘environment’ 24 
(Kendler & Baker 2007) are, in fact, influenced by genetic factors. Environmental measures 25 
can be heritable if there is a bidirectional relationship between an individual’s behaviour and 26 
their environment, if aspects of behaviour are subject to genetic influences (Kendler & Baker 27 
2007; Lynskey & Agrawal 2009). A review of this area identified positive and negative life 28 
 13 
events, divorce and social support all have heritable influences (Kendler & Baker 2007). The 1 
additive genetic correlation may also indicate evocative or active interactions taking place 2 
(Plomin et al. 2013), with genes influencing earlier age of cannabis use opportunity 3 
contributing to individuals selecting into environments and behaviours that facilitate the 4 
development of cannabis dependence. 5 
Alternatively, genetic influences associated with other behaviours may be influencing 6 
progression through the stages of cannabis use. Previous research has identified conduct 7 
disorder influences transitions to cannabis use opportunity, and from opportunity to 8 
dependence (Hines et al. 2016). This is in line with existing research demonstrating the 9 
consistent influence of conduct disorder on drug use (Lynskey et al. 2002; Storr et al. 2011; 10 
Reboussin et al. 2015), and genes relating to conduct disorder and involvement with deviant 11 
peers (Gillespie et al. 2009a) are plausible candidates for the shared genetic liability 12 
between age of opportunity and the development of cannabis abuse/dependence. 13 
Additionally, personality factors associated with drug use (Malmberg et al. 2010), such as 14 
sensation seeking, may underlie this shared genetic liability.  15 
 Cannabis opportunity, frequency of use, and abuse/dependence show a moderate 16 
effect of the unique environment (0.35, 0.26 and 0.22, respectively), but the correlation 17 
between unique environmental influences on opportunity and the later stages of drug use 18 
was non-significant. This may reflect measurement error (Plomin et al. 2013), but is in line 19 
with existing research demonstrating the pattern of environmental factors associated with 20 
progression between specific stages of drug use differs between transitions (Sartor et al. 21 
2007; Belsky DW et al. 2013; Hines et al. 2016). For example, childhood and early 22 
adolescent factors have been shown to be uniquely associated with cannabis opportunity, 23 
whereas escalating other drug use factors is uniquely associated with development of 24 
cannabis dependence (Hines et al. 2016). 25 
 14 
The present analysis indicated none of the observed variance in opportunity to use 1 
cannabis, frequency of use or abuse/dependence in males was attributable to the shared 2 
environment in this sample. The shared environment is usually found to be more important 3 
at earlier stages than later (Fowler et al. 2007), and these findings contradict findings of a 4 
high shared environmental  correlation between cannabis availability and cannabis abuse 5 
(Gillespie et al. 2009b). The samples differ, with the Gillespie et al. findings based on an all-6 
male population, but these contradictory findings indicate cannabis availability (the perceived 7 
ease of obtaining cannabis) and opportunity (having been offered cannabis, or being around 8 
cannabis use) represent different phenotypes.  9 
Previous research has not tested the extent to which genetic influences on cannabis 10 
initiation and cannabis abuse overlap, so comparisons cannot be made to the present 11 
findings for opportunity and abuse/dependence. However, when considered in light of 12 
findings that variation in progression to subsequent use of cannabis is almost entirely 13 
attributable to the unique environment (Hines et al. 2015b), a picture is beginning to emerge 14 
of how different factors influence progression from the very earliest stages of cannabis to the 15 
development of dependence. 16 
Implications 17 
The potential for opportunity to use cannabis to be a marker for intervention has previously 18 
been discussed (Neumark et al. 2012), and the overlap in genetic influences between age of 19 
opportunity and both frequency of cannabis use and cannabis abuse/dependence indicates 20 
there is potential to use this measure to indicate those at greatest risk of developing later 21 
frequent and/ or problematic use. It has previously been suggested that prevention 22 
strategies focused on modifying beliefs, norms and behavioural patterns within close social 23 
networks may be effective at reducing drug use opportunity, and consequently drug use 24 
(Neumark et al. 2012). The identified moderate influence of unique environmental factors on 25 
all phenotypes indicates there is scope to determine further influences which may be 26 
amenable to target within intervention efforts. 27 
 15 
The findings of this paper have important implications for future studies of gene variants and 1 
heritability of problematic cannabis use, and in the choice of controls in case-control studies. 2 
These results indicate only a moderate proportion of genetic influences on cannabis 3 
abuse/dependence are unique from those acting on age of opportunity to use cannabis. 4 
These findings reflect previous research demonstrating the importance of considering drug 5 
use opportunity when looking at the genetics of opiate use (Nelson et al. 2013).  6 
Comparison of participants in treatment for opiate dependence with nondependent 7 
neighbourhood controls (high exposure to illicit drugs, either via use or from residing in 8 
environments with widespread drug availability) identified SNPs in ANKK1 and TTC12 as 9 
associated with heroin dependence, whereas comparison with controls sourced from the 10 
ATR (individuals not dependent on alcohol or illicit drugs, with significantly lower illicit drug 11 
exposure) found no association with these SNPs (Nelson et al. 2013). Until now the 12 
importance of considering cannabis use opportunity in genetic studies has not been 13 
explored, although some studies remove those who have not initiated use. Removing those 14 
who have not initiated cannabis use can reduce sample size and power, and the present 15 
results indicate excluding those without opportunity may avoid conflating genetic influences 16 
whilst retaining a greater proportion of a sample. A further advantage of incorporating 17 
opportunity to use may arise in meta-analyses of genomewide association studies (GWAS) 18 
of cannabis use and misuse. Marked regional variation in opportunity to use across different 19 
samples may comprise an international meta-analytic effort. Exclusion of, or accounting for, 20 
variability in exposure opportunity, even using crude indices of national policy or cannabis-21 
related law, might reduce heterogeneity in the extent to which genetic vulnerability to later 22 
stages of cannabis problems have been adequately expressed.  23 
 Consequently, a key implication of the current findings is the necessity of taking 24 
into consideration the stage of drug use reached amongst the controls for genomic analyses. 25 
Existing research has utilised information on the extent of cannabis use in controls (e.g. 26 
excluding those who had used cannabis fewer than 6 times) (Hartman et al. 2009), but such 27 
 16 
issues are not always taken into consideration (Benyamina et al. 2009). This may be 1 
especially important in studies of cannabis; a drug with high prevalence of use, but relatively 2 
low prevalence of dependence amongst lifetime users. As the legal status of cannabis 3 
changes (Shi et al. 2015) availability may become to be comparable to that of alcohol, but 4 
individual opportunity to use may remain variable. Depending on the research question, and 5 
on the development of research identifying genetic overlap between progression to other 6 
stages of cannabis use and problematic cannabis use, screening controls not only for 7 
opportunity or initiation of cannabis use, but also for frequency of use may have utility in 8 
improving cannabis dependence SNP identification in the future.  9 
 These findings have further implications for the overlap of genetic influences 10 
across drug classes. Existing research has suggested a proportion of the genetic factors 11 
underlying SUDs are not specific to individual drugs, and environmental influences 12 
determine the drug of misuse (Kendler et al. 2003) However, previous research in this area 13 
has not incorporated consideration of the stage sequential nature of drug dependence into 14 
their analyses. Much of the non-specificity of genetic influences on SUDs likely results from 15 
shared influences on the earlier stages of drug use, with more specific influences (such as 16 
those related to drug metabolism, for example) associated with later stages of use. 17 
 18 
Limitations 19 
Certain limitations must be taken into account when interpreting these results. The data are 20 
based on retrospective self-report. Retrospective recall of age onset of drug use behaviours 21 
has been shown to be reliable (Shillington et al. 1995; Johnson & Mott 2001; Parra et al. 22 
2003; Ensminger et al. 2007), but the analyses would benefit from replication in prospective 23 
longitudinal cohorts. Self-report has been shown to be a valid measure of data collection 24 
relating to drug use (Darke 1998), and has been described as the gold standard for 25 
collecting data on phenotypes such as initiation and opportunity (Wagner & Anthony 2002). 26 
Given use of cannabis was illegal at time of data collection, some participants in this study 27 
 17 
may have misreported their drug use. However, the high prevalence of self-reported lifetime 1 
cannabis use (68.5%) suggest it’s unlikely this was an issue. 2 
The results are based on a twin population. Research has demonstrated twin and non-3 
twin populations do not differ in incidence of psychiatric illness (Kendler et al. 1996), and no 4 
association has been found between twin environmental similarity and mental health 5 
outcomes (Kendler et al. 1993).  6 
Conclusions 7 
There are significant genetic contributions to lifetime cannabis abuse/dependence, but a 8 
proportion of this overlaps with genetic influences acting on the opportunity to use cannabis 9 
and the frequency of cannabis use. Individuals without drug use opportunity are 10 
uninformative, and studies of drug use disorder and frequency of use, whether focused on 11 
identifying gene variants or environmental factors, must incorporate consideration of drug 12 
use exposure use amongst controls in order to accurately identify aetiological factors.  13 
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Table 1: Tetrachoric correlations (95% confidence intervals) between age of opportunity to 1 
use cannabis and cannabis abuse/dependence in MZ and DZ twin pairs 2 
 3 
 Within trait, across twin correlation Across trait, across twin correlation 
Age of 
Opportunity  
twin 1/twin 2 
Frequency 
cannabis use 
twin 1/twin 2 
Abuse/ 
Dependence 
Twin 1/twin 2 
Age of 
Opportunity / 
Frequency 
cannabis use 
Age of 
Opportunity / 
Abuse/ 
Dependence 
Frequency 
cannabis use/ 
Abuse/ 
Dependence 
MZ 
N = 1709 
0.65 
(0.57 – 0.71) 
0.72 
(0.63 – 0.75) 
0.79 
(0.66 – 0.82) 
0.48 
(0.40 – 0.55) 
0.37 
(0.26 – 0.48) 
0.67 
(0.65 - 0.75) 
DZ 
N = 1594 
0.36 
(0.26 – 0.45) 
0.48 
(0.38 – 0.58) 
0.37 
(0.26 – 0.48) 
0.31 
(0.22 – 0.38) 
0.22 
(0.12 – 0.33) 
0.41 
(0.29 – 0.52) 
 4 
  5 
 25 
Table 2: Proportion of variance (95% CI) attributable to additive genetic (A), shared 1 
environment (C) and unique environment (E) factors in the fully estimated and in the most 2 
parsimonious model 3 
  Opportunity Frequency Dependence Correlation 
Opportunity 
– Frequency 
Correlation 
Opportunity 
–
Dependence 
Correlation 
Frequency – 
Dependence 
Fully 
estimated 
ACE model 
A 0.57 
(0.34 – 0.69) 
0.46 
(0.22 – 0.70) 
0.64 
(0.33 – 0.84) 
0.35 
(0.18 – 0.54) 
0.27 
(0.08 – 0.46) 
0.49 
(0.24 – 0.70) 
C 0.07 
(0.00 – 0.27) 
 
0.25 
(0.04 – 0.45) 
0.13 
(0.00 – 0.38) 
0.13 
(-0.03 – 027) 
0.09 
(-0.05 – 
0.23) 
0.18 
(0.02 – 0.38) 
E 0.35 
(0.28 – 0.43) 
 
0.28 
(0.23 – 0.36) 
0.23 
(0.13 – 0.36) 
 
-0.02 
(-0.08 – 
0.05) 
 
0.01 
(-0.08 - 0.10) 
0.22 
(0.14 – 0.31) 
 
Parsimonious 
AE model 
A 0.65 
(0.58 – 0.72) 
0.74 
(0.66 – 0.80) 
 
0.78 
(0.65 – 0.88) 
0.47 
(0.41 – 0.52) 
0.37 
(0.30 – 0.44) 
 
0.68 
(0.59 – 0.75) 
E 0.35 
(0.29 – 0.42) 
0.26 
(0.20 – 0.34) 
0.22 
(0.12 – 0.35) 
- - 0.21 
(0.14 – 0.29) 
 
 4 
